Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Therapeutic options for mucinous ovarian carcinoma.

Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL.

Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31836-0. doi: 10.1016/j.ygyno.2019.12.015. [Epub ahead of print]

2.

The molecular origin and taxonomy of mucinous ovarian carcinoma.

Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringe KL.

Nat Commun. 2019 Sep 2;10(1):3935. doi: 10.1038/s41467-019-11862-x.

3.

The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.

Chin-Lenn L, De Boer RH, Segelov E, Marx GM, Hughes TM, McCarthy NJ, White SC, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Gorelik A, Mann GB.

Asia Pac J Clin Oncol. 2018 Dec;14(6):410-416. doi: 10.1111/ajco.13075. Epub 2018 Sep 30.

PMID:
30270527
4.

Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.

Meiser B, Quinn VF, Mitchell G, Tucker K, Watts KJ, Rahman B, Peate M, Saunders C, Geelhoed E, Gleeson M, Barlow-Stewart K, Field M, Harris M, Antill YC, Susman R, Bowen MT, Mills L, Kirk J; TFGT Collaborative Group.

Eur J Hum Genet. 2018 Jul;26(7):972-983. doi: 10.1038/s41431-017-0057-3. Epub 2018 Mar 30.

5.

Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy.

Smith K, Winstanley J, Boyle F, O'Reilly A, White M, Antill YC.

Support Care Cancer. 2018 Feb;26(2):483-489. doi: 10.1007/s00520-017-3852-z. Epub 2017 Aug 22.

PMID:
28831569
6.

Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.

Pittman K, Antill YC, Goldrick A, Goh J, de Boer RH.

Asia Pac J Clin Oncol. 2017 Aug;13(4):266-276. doi: 10.1111/ajco.12517. Epub 2016 Nov 10. Review.

PMID:
27862983
7.

Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial.

Quinn VF, Meiser B, Kirk J, Tucker KM, Watts KJ, Rahman B, Peate M, Saunders C, Geelhoed E, Gleeson M, Barlow-Stewart K, Field M, Harris M, Antill YC, Cicciarelli L, Crowe K, Bowen MT, Mitchell G.

Genet Med. 2017 Apr;19(4):448-456. doi: 10.1038/gim.2016.130. Epub 2016 Sep 29.

PMID:
27684037
8.

When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.

Meiser B, Quinn VF, Gleeson M, Kirk J, Tucker KM, Rahman B, Saunders C, Watts KJ, Peate M, Geelhoed E, Barlow-Stewart K, Field M, Harris M, Antill YC, Mitchell G.

Eur J Hum Genet. 2016 Nov;24(11):1517-1523. doi: 10.1038/ejhg.2016.69. Epub 2016 Jun 22.

9.

Lynch syndrome and cervical cancer.

Antill YC, Dowty JG, Win AK, Thompson T, Walsh MD, Cummings MC, Gallinger S, Lindor NM, Le Marchand L, Hopper JL, Newcomb PA, Haile RW, Church J, Tucker KM, Buchanan DD, Young JP, Winship IM, Jenkins MA.

Int J Cancer. 2015 Dec 1;137(11):2757-61. doi: 10.1002/ijc.29641. Epub 2015 Jul 14.

10.

Cancer risks for MLH1 and MSH2 mutation carriers.

Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, Antill YC, Thibodeau SN, Casey G, Gallinger S, Marchand LL, Newcomb PA, Haile RW, Young GP, James PA, Giles GG, Gunawardena SR, Leggett BA, Gattas M, Boussioutas A, Ahnen DJ, Baron JA, Parry S, Goldblatt J, Young JP, Hopper JL, Jenkins MA.

Hum Mutat. 2013 Mar;34(3):490-7. doi: 10.1002/humu.22262.

11.

Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles.

Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, Tothill RW, Thorne H; kConFab, Barnes DR, Li J, Ellul J, Philip GK, Antill YC, James PA, Trainer AH, Mitchell G, Campbell IG.

PLoS Genet. 2012 Sep;8(9):e1002894. doi: 10.1371/journal.pgen.1002894. Epub 2012 Sep 27.

12.

Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.

Duffy DL, Antill YC, Stewart CJ, Young JP; kConFab, Spurdle AB.

Twin Res Hum Genet. 2011 Apr;14(2):111-8. doi: 10.1375/twin.14.2.111.

PMID:
21425892
13.

Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers.

Win AK, Dowty JG, Antill YC, English DR, Baron JA, Young JP, Giles GG, Southey MC, Winship I, Lipton L, Parry S, Thibodeau SN, Haile RW, Gallinger S, Le Marchand L, Lindor NM, Newcomb PA, Hopper JL, Jenkins MA.

Obstet Gynecol. 2011 Apr;117(4):899-905. doi: 10.1097/AOG.0b013e3182110ea3.

14.

Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers.

Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Di Iulio J, Lindeman GJ, Kirk J, Phillips KA, Campbell IG.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):265-74. doi: 10.1158/1055-9965.EPI-09-0359.

15.

Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.

Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ; kConFab Investigators.

Clin Cancer Res. 2008 May 15;14(10):2953-61. doi: 10.1158/1078-0432.CCR-07-5237. Epub 2008 Apr 29.

16.

Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale.

Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Phillips KA, Campbell IG.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1396-8.

17.

Screening behavior in women at increased familial risk for breast cancer.

Antill YC, Reynolds J, Young MA, Kirk JA, Tucker KM, Bogtstra TL, Wong SS, Dudding TE, Di Iulio JL, Phillips KA.

Fam Cancer. 2006;5(4):359-68. Epub 2006 Jul 7.

PMID:
16817030
18.

Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation.

Mitchell G, Antill YC, Murray W, Kirk J, Salisbury E, Lindeman GJ, Di Iulio J, Milner AD, Devereaux L, Phillips KA.

Breast Cancer Res. 2005;7(6):R1122-31. Epub 2005 Nov 14.

Supplemental Content

Loading ...
Support Center